Product Name:(S)-3-(Boc-amino)pyrrolidine

IUPAC Name:tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate

Molecular Formula:C9H18N2O2
Catalog Number:CM102456
Molecular Weight:186.26

Packing Unit Available Stock Price($) Quantity
CM102456-25g in stock ǠȌ
CM102456-100g in stock ſſdž

For R&D use only.

Inquiry Form


Product Details

CAS NO:122536-76-9
Molecular Formula:C9H18N2O2
Melting Point:-
Smiles Code:O=C(N[C@@H]1CNCC1)OC(C)(C)C
Catalog Number:CM102456
Molecular Weight:186.26
Boiling Point:
MDL No:MFCD00143194
Storage:Store at room temperature.

Category Infos

Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

Column Infos

Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.